Correlation between p53 mutations and antibody staining in breast carcinoma

Abnormalities of the p53 gene and protein were examined in 81 primary breast carcinoma samples. Using a polymerase chain reaction-single-strand conformational polymorphism (PCR-SSCP) analysis, mutations in p53 exons 5-8 were identified in 13 of 81 tumours (16 per cent) and confirmed by DNA seguencing. Positive staining for p53 protein was detected in ten of 77 (13 per cent) of these tumours using polyclonal CM1 antibody on formalin-fixed tissue. Mutations detected by PCR-SSCP analysis were more common in grade III tumours (P=0.015), but no correlation was found with tumour size, node status or level of epidermal growth factor receptor expression. A p53 mutation was associated with positive antibody staining in only two patients

[1]  N. Maitland,et al.  Nucleic acid probes in the study of latent viral disease. , 2007, Journal of oral pathology.

[2]  B. Vojtesek,et al.  Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. , 1994, British Journal of Cancer.

[3]  R. Vile.  p53: a gene for all tumours? , 1993, BMJ.

[4]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[5]  T. Visakorpi,et al.  Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. , 1992, Journal of the National Cancer Institute.

[6]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[7]  S. Friend,et al.  Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. , 1992, The New England journal of medicine.

[8]  H. J. Evans,et al.  p53 allele losses, mutations and expression in breast cancer and their relationship to clinico‐pathological parameters , 1992, International journal of cancer.

[9]  D. Lane,et al.  Expression of p53 protein in infiltrating and in‐situ breast carcinomas , 1991, The Journal of pathology.

[10]  S. Friend,et al.  Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Bartek,et al.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. , 1991, Oncogene.

[12]  P. Green,et al.  Identification of p53 gene mutations in bladder cancers and urine samples. , 1991, Science.

[13]  B. Angus,et al.  p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study , 1991, The Journal of pathology.

[14]  B. Vogelstein,et al.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.

[15]  J. Bartek,et al.  Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro , 1990, International journal of cancer.

[16]  W. Lowry,et al.  Allele loss from chromosome 17 in ovarian cancer. , 1990, Oncogene.

[17]  A. Harris,et al.  Increased expression of mutant forms of p53 oncogene in primary lung cancer , 1990, The Lancet.

[18]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[19]  V. Murray.  Improved double-stranded DNA sequencing using the linear polymerase chain reaction. , 1989, Nucleic acids research.

[20]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[21]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[22]  P. Devilee,et al.  At least four different chromosomal regions are involved in loss of heterozygosity in human breast carcinoma. , 1989, Genomics.

[23]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[24]  A. Forrest,et al.  ALLELE LOSS ON SHORT ARM OF CHROMOSOME 17 IN BREAST CANCERS , 1988, The Lancet.

[25]  A. Harris,et al.  Quantitative assays of epidermal growth factor receptor in human breast cancer: Cut‐off points of clinical relevance , 1988, International journal of cancer.

[26]  F. Rilke,et al.  P53 expression in breast cancer , 1988, International journal of cancer.

[27]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[28]  J. Haybittle,et al.  The cancer research campaign (King's/Cambridge trial for early breast cancer: clinico-pathological aspects. , 1982, British Journal of Cancer.

[29]  A. Levine,et al.  Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells , 1981, Molecular and cellular biology.

[30]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[31]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[32]  D. Lane,et al.  High levels of p53 protein in UV-irradiated normal human skin. , 1993, Oncogene.

[33]  A. Gown,et al.  Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. , 1992, The American journal of pathology.

[34]  J. Bartek,et al.  Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. , 1992, Journal of cell science.

[35]  Carl W. Miller,et al.  Human p53 gene localized to short arm of chromosome 17 , 1986, Nature.